Literature DB >> 28003277

Genetics of β-Amyloid Precursor Protein in Alzheimer's Disease.

Julia Tcw1, Alison M Goate1.   

Abstract

Alzheimer's disease (AD) is characterized neuropathologically by neuronal cell loss, extracellular neuritic plaques composed of β-amyloid (Aβ), and intracellular neurofibrillary tangles composed of hyperphosphorylated tau protein. Aβ is generated by proteolytic processing of the β-amyloid precursor protein (APP). Most individuals with Down syndrome (DS) have three copies of APP, leading to elevated APP expression, increased Aβ deposition, and characteristic AD neuropathology. Sequencing of APP in familial early-onset AD identified missense mutations that cause AD, while a recently discovered coding variant, APP A673T, reduces the risk for AD. Cellular and animal studies show that risk-associated mutations increase total Aβ levels, Aβ42 levels, or Aβ fibrillogenesis, while protective alleles reduce Aβ levels. Together, these studies provide compelling evidence for the Aβ hypothesis and suggest that therapeutics that reduces Aβ levels or Aβ fibrillogenesis should lower the risk for or prevent AD.
Copyright © 2017 Cold Spring Harbor Laboratory Press; all rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28003277      PMCID: PMC5453386          DOI: 10.1101/cshperspect.a024539

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Med        ISSN: 2157-1422            Impact factor:   6.915


  32 in total

Review 1.  Neurodegenerative Disease Transmission and Transgenesis in Mice.

Authors:  Brittany N Dugger; Daniel P Perl; George A Carlson
Journal:  Cold Spring Harb Perspect Biol       Date:  2017-11-01       Impact factor: 10.005

Review 2.  Alzheimer Disease: An Update on Pathobiology and Treatment Strategies.

Authors:  Justin M Long; David M Holtzman
Journal:  Cell       Date:  2019-09-26       Impact factor: 41.582

Review 3.  A short perspective on the long road to effective treatments for Alzheimer's disease.

Authors:  David S Reynolds
Journal:  Br J Pharmacol       Date:  2019-03-01       Impact factor: 8.739

4.  Expression of AHI1 Rescues Amyloidogenic Pathology in Alzheimer's Disease Model Cells.

Authors:  Lai-Lei Ting; Hsien-Tsung Lu; Shu-Fen Yen; Thi Huong Ngo; Fang-Yu Tu; I-Shih Tsai; Yi-Hua Tsai; Fu-Yen Chang; Xiao-Jiang Li; Shihua Li; Ching-Kuo Lee; Shu-Huei Kao; Yu-Min Kuo; Yung-Feng Lin
Journal:  Mol Neurobiol       Date:  2019-05-07       Impact factor: 5.590

5.  Pharmacogenomics of Alzheimer's Disease: Novel Strategies for Drug Utilization and Development.

Authors:  Ramón Cacabelos; Vinogran Naidoo; Olaia Martínez-Iglesias; Lola Corzo; Natalia Cacabelos; Rocío Pego; Juan C Carril
Journal:  Methods Mol Biol       Date:  2022

Review 6.  Exploring the Involvement of the Amyloid Precursor Protein A673T Mutation against Amyloid Pathology and Alzheimer's Disease in Relation to Therapeutic Editing Tools.

Authors:  Gabriela Dumitrita Stanciu; Daniela Carmen Ababei; Razvan Nicolae Rusu; Veronica Bild; Bogdan-Ionel Tamba
Journal:  Pharmaceutics       Date:  2022-06-15       Impact factor: 6.525

7.  Amyloidogenic processing of amyloid β protein precursor (APP) is enhanced in the brains of alcadein α-deficient mice.

Authors:  Naoya Gotoh; Yuhki Saito; Saori Hata; Haruka Saito; Daiki Ojima; Chiaki Murayama; Mayo Shigeta; Takaya Abe; Daijiro Konno; Fumio Matsuzaki; Toshiharu Suzuki; Tohru Yamamoto
Journal:  J Biol Chem       Date:  2020-05-27       Impact factor: 5.157

8.  Leveraging omic features with F3UTER enables identification of unannotated 3'UTRs for synaptic genes.

Authors:  Mina Ryten; Harpreet Saini; Juan A Botia; Siddharth Sethi; David Zhang; Sebastian Guelfi; Zhongbo Chen; Sonia Garcia-Ruiz; Emmanuel O Olagbaju
Journal:  Nat Commun       Date:  2022-04-27       Impact factor: 17.694

Review 9.  Non-canonical soluble amyloid-beta aggregates and plaque buffering: controversies and future directions for target discovery in Alzheimer's disease.

Authors:  David L Brody; Hao Jiang; Norelle Wildburger; Thomas J Esparza
Journal:  Alzheimers Res Ther       Date:  2017-08-17       Impact factor: 6.982

Review 10.  How Surrogate and Chemical Genetics in Model Organisms Can Suggest Therapies for Human Genetic Diseases.

Authors:  Katherine A Strynatka; Michelle C Gurrola-Gal; Jason N Berman; Christopher R McMaster
Journal:  Genetics       Date:  2018-03       Impact factor: 4.562

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.